Beigene Ltd

BeiGene Ltd. was incorporated in 2010 with its headquarters located in Beijing, China. Operating in the biotechnology and pharmaceutical industry, the company's core business segments involve the discovery, development, manufacturing, and commercialization of innovative molecularly targeted and immuno-oncology drugs for cancer treatment. Although BeiGene Ltd. is not associated with conventional consumer brands, it has developed pharmaceutical products such as BRUKINSA® (zanubrutinib), used to treat mantle cell lymphoma (MCL), and tislelizumab, a PD-1 antibody indicated for various tumor types. Its products and services have a global reach, with significant markets that include China, the United States, and several European countries. (Powered by AI)